Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apixaban vs VKA and aspirin vs placebo in atrial fibrillation with recent ACS and/or PCI
NL-OMON47141Phase 3Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2017
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of apixaban, warfarin and aspirin in Atrial fibrillation (AFib), acute coronary syndrome (ACS) and coronary arteriosclerosis (4 arms), sponsored by Bristol Myers Squibb. Primary endpoint: ISTH major or clinically relevant non-major bleeding. Started Oct 2017; status: active, not recruiting.
02
Drugs
apixabanwarfarinaspirin
03
Conditions
Atrial fibrillation (AFib)acute coronary syndrome (ACS)coronary arteriosclerosis
Beyond the preview
Go deeper on NL-OMON47141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47141.